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Dose Time Response Modeling of Neurobehavioral Screening Data:
Application of Physiologically Relevant Parameters to Allow for Dose
Dependent Time of Peak Effects
Michael Raymond Wessel
ABSTRACT
In collaboration with the United States Environmental Protection
Agency (USEPA), the University of South Florida Health Risk
Methodology Group has developed dose-time-response models to
characterize neurobehavioral response to chemical exposure. The
application of dose-time-response models to neurobehavioral
screening tests on laboratory animals allows for benchmark dose
estimation to establish exposure limits in environmental risk
assessment. This thesis has advanced dose-time-response modeling
by generalizing a published toxico diffusion model to allow for dose
dependent time of peak effects. To accomplish this, a biphasic model
was developed which adopted the effect compartment model paradigm
used in pharmacokinetics/pharmacodynamics to estimate a
distributional rate constant to account for dose related variation in the
time of peak effect. The biphasic model was able to describe dosedependent time of peak effects as observed in the data on acute
exposure to parathion and adequately predicted the observed
response. However, the experimental design appeared insufficient in
statistical power to confirm statistical significance for each parameter
of interest. Motivated by the question of what design requirement
might be necessary to validate the biphasic model, Monte Carlo
simulation was adopted. Simulations were performed to assess the
efficacy and efficiency of various experimental designs for detecting
and evaluating some critical characteristics of the biphasic model,
including the TOPE. The results of simulation suggest that the location
of measurement times around the TOPE have important implications
for assessing the statistical significance of the parameter that
describes dose-dependent TOPE and that the mean squared error of
the parameter estimator was improved most when testing times were
vii

chosen to bracket the TOPE. While dose dependent time of peak
effects has underlying physiological mechanisms such as synergistic or
capacity limited kinetics, the biphasic model estimates these
physiological properties through a mathematical function which may
be physiologically relevant but does not necessarily define
physiological mechanisms underlying the response. However, if
verified through further testing, the biphasic model may contribute to
the USEPA’s aim of developing physiologically relevant dose-response
models for assessing risk of neurotoxicity with repeated measurements
of response.
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Chapter One
Introduction
Chemical exposure has become a certainty of human life in the
21st century. In fact, it is difficult to imagine a day goes by in which
one is not exposed to a chemical, natural or synthetic, about which
there is some uncertainty of risk. Formal attempts to characterize the
risks associated with chemical exposure date back to Hippocrates
(ancient 400 BC) who developed toxicological principles related to
clinical observations on the bioavailability and absorption of common
therapies and poisons. Paracelsus (~1500 AD) is credited with the idea
that all substances are poisons and it is the dose that determines its
potential risk and benefit. In modern times, exponential growth in the
production of chemicals occurred as a consequence of the industrial
revolution and World War II and in the United States led to the
establishment of regulatory agencies such as the Food and Drug
Administration and later the Environmental Protection Agency (US
EPA). Because of the many natural and synthetic chemicals introduced
in today’s environment, governmental agencies throughout the
industrialized world have become keenly interested in assessing the
potential risks to humans from toxic agents (US EPA, 1998). In the
1

US, the EPA has registered more than 65,000 chemical substances
manufactured, imported, or processed in the United States under the
Toxic Substance Control Act (TSCA) (US EPA, 1996). Chemical
exposure has become one of the ten leading causes of workplace
disorder (Anger, 1984) and the potential for adverse effects on the
nervous system is becoming common in the workplace as
approximately 70 chemicals of known neurotoxic potential have
potential exposure to more than 1 million workers (Anger,1990).
1.1 Health Risk Assessment
Environmental risk assessment is an emerging field that relies on
three basic assessment principles: exposure assessment, hazard
characterization, and risk quantification (McCarty and Mackay, 1993).
The EPA’s National Center for Environmental Assessment (NCEA)
conducts risk assessment for an array of health effects that may result
from exposure to environmental agents. This process includes a
thorough evaluation of all the available data as well as conducting
scientific experiments to understand the relationship between
exposure and risk. Historically, these analyses have been done very
differently for cancer and non-cancer health effects because of
perceived differences in the mechanistic underpinnings of cancer and
other toxic effects. As our understanding of the underlying biology of
toxic effects has grown, however, the apparent differences between
2

cancer and non-cancer effects have lessened to the point where it
seems reasonable to develop quantitative methods based on similar
considerations for all types of health effects, and to make approaches
to risk assessment as consistent across health endpoints as our
current mechanistic understanding allows (US EPA, 2000).
Neurotoxicity risk assessment is one area in particular where the EPA
has expressed the need for consistent guidance on how to evaluate
data on neurotoxic substances and assess their potential to cause
transient or persistent and direct and indirect effects on human health.
1.2 Neurotoxicity
Neurotoxicity is defined as an adverse change in the structure or
function of the central and/or peripheral nervous system following
exposure to a chemical, physical or biological agent (Tilson, 1990).
The central nervous system is particularly vulnerable to chemical insult
and has limited ability to regenerate. Functional neurotoxic effects
include adverse changes in somatic/ autonomic, sensory, motor and/or
cognitive function (US EPA, 1998). The effects can be transient (the
organism returns to pre-exposure condition) or persistent (the
organism is permanently and adversely changed by exposure).
However, even transient effects can signify underlying resultant
damage to the organism (US EPA, 1998). Animal studies make up the
largest portion of controlled exposure assessments and allow for the
3

use of high concentrations of chemicals to be administered to achieve
responses that may define the mechanism of action as well as the
magnitude of response to chemical exposure. Neurotoxic screening
tests such as the Functional Observational Battery (FOB) test (Moser
et al., 1995, 1997a), along with neuro-physiological, biochemical,
neuro-pathological and neuro-endocrinological studies are now being
used by the EPA as an overall strategy to detect the full range of
chemical induced alterations in the structure and function of the
nervous system.
The advancement of neurotoxicity testing methods and
experimental design has coincided with advances in statistical
methodologies and computer applications to allow for more effective
methods of performing risk assessments on neurotoxins. A significant
advance in neurotoxicity risk assessment is the use of benchmark dose
(BMD) methodologies for establishing safety levels of chemical
exposure (US EPA, 2000). While traditional analysis of FOB data has
used Analysis of Variance (ANOVA) to set a No Observed Adverse
Effects Level (NOAEL), dose-time-response models provide continuous
estimation of response over the time course of the study providing
beneficial information for BMD estimation.
The University of South Florida’s Health Risk Assessment
Methodology Group (HRAMG) has been working to develop new
4

statistical methods for explicit dose-time-response models (DTR) of
the FOB data, which may serve as the foundation for benchmark dose
estimation. The development of explicit DTR models to describe
neurotoxic potential of chemical exposure has progressed from strictly
mathematical models such as polynomial models to those
incorporating simple toxicokinetics. The potential for physiologic
interpretation enhances comparability with other available data and
increases confidence in the interspecies extrapolation of results of
these screening tests to characterize potential risk to human health.
Zhu (2005a) and Zhu et al. (2005b,c) have developed a family of
dose-response models and illustrated their application through several
published datasets generated from the EPA Superfund study (Moser et
al, 1995) and a study conducted in collaboration with the International
Program on Chemical Safety (IPCS) (Moser et al. 1997a). These
models incorporate basic toxicokinetic principles into a family of
mathematical models in consideration of the physical properties
underlying responses to chemical exposure observed in the FOB data.
Zhu (2005 b,c) found that the toxico diffusion model often
satisfactorily described the observed dose-response relationship in FOB
data and is useful in application of benchmark dose estimation
methods. While the toxico diffusion model has proven robust in
describing FOB data, it is limited in describing the full possible range of
5

dose related response to acute exposure. Most importantly this model
is limited by imposing a dose independent Time of Peak Effect (TOPE)
across every exposure level.
1.3 Thesis Objectives
The first objective of this thesis was to expand on a published
toxico-diffusion function used to model neurobehavioral screening data
by considering a situation where the TOPE may take on dosedependent characteristics. Through the incorporation of a dosedependent distributional parameter, this thesis proposes a “biphasic
diffusion” model and illustrates the utility of this model on the analysis
of a FOB dataset on the motor activity of laboratory rats exposed to
the organophosphate pesticide parathion.
A second objective of the thesis was to investigate the study
design requirements necessary to recover the key characteristics of
the biphasic model, especially dose-dependent time of peak effect.
Monte Carlo simulation was adopted to explore the potential FOB
testing times as well as sample size with respect to the efficiency and
effectiveness of recovering key components of the biphasic model.
Various designs were compared using statistical measures of bias,
power, mean squared error, and confidence interval. Utility of
alternative study designs may contribute to the USEPA’s aims toward
6

using dose-response modeling, particularly with physiologically
relevant models, to assess potential risks of chemical exposure to
human health.

7

Chapter 2
Neurobehavioral Screening Tests
2.1

Screening Tests
Screening tests for neurotoxicity represent the most

fundamental level of investigation for forecasting potential
neurotoxicity in animal studies (WHO 1986). Screening tests are
widely used because they are simple, rapid and economical. A battery
of measurements is acquired with these tests that include
measurements of behavioral endpoints representing neurophysiological, neuro-muscular, autonomic and sensorimotor functions.
Behavioral endpoints reflect the integration of various functional
components of the nervous system and are often used as surrogates
for mechanistic processes involved in a subjects response to exposure
of a chemical agent. The EPA’s testing guidelines developed for the
Toxic Substances Control Act (TSCA) and the Federal Insecticide,
Fungicide, and Rodenticide Act described the use of neurobehavioral
screening tests and established protocols and procedures used in these
experimental designs (US EPA, 1991). Since that time the protocols
and procedures have been refined and are evolving to become a
8

standardized first tier screening method for neurotoxicity (US EPA,
1998). These toxicological studies, known as Functional Observational
Battery (FOB) tests, are simple to implement, relatively non-invasive
and generate behavioral change rapidly.
2.2

IPCS Functional Observational Battery Tests
This thesis utilizes data from a Functional Observational Battery

(FOB) as described in Moser et al. (1997a) and implemented in the
IPCS’ collaborative study. For acute exposure, the study protocol uses
5 dose levels including a control group and 4 testing times (including a
baseline measurement) to assess time-related response to chemical
exposure. The dose levels and the second testing time were
determined via a dose range finding study. Given the cooperative
nature of the IPCS sponsored studies several laboratories participated
in these studies yielding several independent estimates of doseresponse for many of the chemicals tested.
Prior to initiation of the FOB testing a dose range finding study
was performed to determine the dosing regime and testing times for a
hypothesized time of peak chemical effect (TOPE) (Moser et al.,
1997b). The starting dose was chosen based loosely on published
estimates of the LD50 (dose which would be lethal to 50% of the
subjects). Three doses at constant intervals above and below the
starting dose were used for a seven day survival study to determine
9

the top nonlethal dose to use in the FOB studies. The dose levels used
for the FOB designs were then 100%, 50% 25% and 12.5% of the top
nonlethal dose. A separate pilot study was then conducted to estimate
the TOPE using gait and arousal scores. Thus, the TOPE estimated for
gait and arousal scores were taken to represent a hypothesized TOPE
for all neurobehavioral endpoints.
Ten animals were randomly assigned to each dose group for the
FOB studies. Testing times were established such that a FOB was
conducted prior to exposure and at 2-3 subsequent time points after
exposure. The first post-exposure testing time was conducted to
correspond with the TOPE of the chemical being tested. Subsequent
tests were performed at one day and then one week after exposure.
Post exposure test times generally did not exceed one week.
The FOB response variables consisted of 25- 30 non-invasive
measures designed to assess behavioral alterations with respect to a
wide range of neurobiological functions, including sensory, motor and
autonomic functions, excitability, neuromuscular strength, and activity
level. The entire battery of tests required approximately 6-8 minutes
per rat. Assessment of motor activities was used in conjunction with
the FOB because of its long history of use for evaluating behavioral
effects of chemicals (MacPhail et al., 1989). Motor activity counts
represent a broad class of behaviors involving coordinated
10

participation of sensory, motor, and integrative processes. Neurotoxic
agents can lead to either increases or decreases in motor activity
counts and organophosphate pesticides such as parathion, the
chemical studied in this thesis, have been shown to decrease motor
activity counts in neurobehavioral screening studies (USEPA, 1998).
The apparatus for motor activity test was left to the discretion of
participating laboratories, provided several criteria were met (Moser et
al., 1997a). This thesis used parathion motor activity counts to
illustrate fitting the biphasic toxico-diffusion model to neurobehavioral
screening data.
2.3

Assessment Methodologies
The USF Health Risk Assessment Methodology Group (HRAMG)

has used the FOB to develop and test several classes of mathematical
models to predict neurobehavioral response to chemical exposure. Liu
(2000) developed polynomial models for continuous FOB outcomes;
Woodruff (2001) developed a diffusion model that is flexible in
describing both transient and persistent nonlinear dose-response
relationships seen in the FOB data; Zhu (2001) tested these models on
a large number of FOB datasets from both the EPA Superfund and the
IPCS studies. More recently Zhu (2005a) developed a class of
mathematical models that allow for incorporation of toxicokinetics, and
in a series of reports (Zhu et al. 2005a,b) applied these models to the
11

FOB datasets and illustrated their use in benchmark dose estimation.
Common in these statistical analyses was the use of random effects to
adjust for biological variation in responses among animals. These
models performed well for describing the dose-response patterns
observed in the FOB studies. However, physiological relevance of these
models relies on simplifying assumptions such as linear or singlecompartment kinetics. It would be beneficial to derive models capable
of describing exposure related response as well as incorporate
parameters that estimate well known physiological phenomena that
regulate the time course of a chemicals presence in the body and its
affect on the observed response when the system displays
nonlinearities such as nonlinear uptake or saturation kinetic processes.
Understanding of this process begins with knowledge of how the body
processes the chemical (pharmacokinetics/toxicokinetics) and
subsequent characterization of how the concentration of the chemical
affects the organism of study (pharmacodynamics/toxicodynamics).

12

Chapter 3
Pharmacokinetics and Pharmacodynamics
In this thesis, references are made to pharmacokinetic and
pharmacodynamic (PK/PD) modeling techniques to develop a
background on which the generalized biphasic toxico diffusion model
was based. It should be noted that while the terms pharmacokinetics
and toxicokinetics have essentially parallel meaning in their respective
fields, in the strictest sense the former term should be restricted to the
field of pharmacology. Since much of the literature devoted to kinetic
and dynamic properties of chemical exposure has arisen from the field
of pharmacology, we define the modeling approach using the PK/PD
modeling paradigm and apply the biphasic model to a toxicological
study.
3.1 Compartmental Pharmacokinetics
Orthodox pharmacokinetic and toxicokinetic studies deal with
changes of drug concentrations in the plasma or an organ over time in
an attempt to describe how the body absorbs, distributes and
eliminates a drug (Torda et al. 1994). The compartmental approach to
pharmacokinetic estimation views the body as being composed of a
13

number of pharmacokinetically distinct compartments. Each
compartment can be thought of as an imaginary space in the body
representing a combination of various tissues and organs, among
which the drug interacts. Anatomical composition of the compartment
is unknown and in most cases its analysis is often of little value (Kwon
2002). Compartmental models are designed to provide a conceptual
understanding of distributional behaviors of a drug between the
plasma and other tissues or organs in the body and estimate various
pharmacokinetic parameters including plasma concentrations,
apparent volumes of distribution and rates governing elimination and
clearance. It is recognized that these compartment models, while
estimating physiological properties, still represent empirical fits to the
data. However, the physiological interpretations are important for
extrapolating information from animal studies to regulatory data on
human health (US EPA 1998). Consider, for example, the simplest of
pharmacokinetic models describing IV bolus injection of a substance
into the circulatory system and subsequent elimination (Ke) from the
body (Figure 1).

14

Chemical

Cp
Ke

Figure 1. Illustration of simple one compartment pharmacokinetic
model

Concentration of the chemical in the compartment is highest
immediately after injection and concentration at any time t is governed
(-K *t)
e

by a single exponential rate of elimination: Cp(t) = C0*e
Where;

Cp(t) = Concentration in the circulatory system at time t
C0 = Concentration of chemical immediately after IV bolus injection
(-K *t)
e

e

= an exponential elimination rate constant.

This first order, mono-exponential function is typically used to model
plasma concentration versus time curves with direct injection into a
central compartment yielding estimates of compartment volume and
chemical elimination. One compartment behavior of plasma
concentration does not necessarily imply that the chemical is at the
same concentration in all the tissues and organs in the body. Rather,

15

this implies that the concentrations are in instantaneous equilibrium
with those in the plasma upon drug administration.
An expansion of the one-compartmental approach to
pharmacokinetic modeling is to allow for the distribution of the
chemical from the plasma compartment into a peripheral compartment
(brain, muscle tissue, etc). When distribution of a chemical from the
plasma into certain organs or tissues is substantially different from the
central compartment, multi-compartment models allow for the
incorporation of one, or several, peripheral compartments (Figure 2).

K12

Chemical

Ka

C1(t)

C2(t)

K21

Ke

Figure 2. Two compartment PK model describing the
pathway of chemical introduction and elimination from
an organism
The two compartment model is typically defined where the
administered chemical is delivered and eliminated from the central
compartment and distribution between the central and peripheral
compartments is controlled via two distribution micro-constants (K12
16

and K21) characterized by the distribution constant Ka (Gabrielsson and
Weiner 2000). When these rate constants reach a steady state, then
the distribution of the chemical reaches equilibrium and the
mechanism governing concentration in the central compartment is
controlled through the elimination rate Ke . Methods of estimating the
concentration in the central compartment via a two compartment
paradigm include the bi-exponential function
Cp(t)=θ1e-Ka*t + θ2e-Ke*t
where Ka represents the distribution phase from the plasma that
includes absorption into the second compartment and Ke represents
the post equilibrium or terminal elimination phase governed by
elimination of the chemical from the central compartment. Chemical
concentration in the plasma is highest immediately after injection in
the two-compartment model and behaves similarly to the one
compartment model except initially when absorption into the second
compartment causes an accelerated depletion of the chemical
concentration from the central compartment (Figure 3).

17

Distribution phase

Terminal elimination phase
Log Cp(t)

Time

Figure 3. Bi-exponential decline of concentration in the
central compartment after iv bolus injection when chemical
distribution can be described using two-compartment
model (Taken from Kwon 2002).
3.2

Nonlinear Kinetics
Any pharmacokinetic process of a chemical (i.e. absorption,

distribution, metabolism or excretion) that cannot be described with
first order (linear) kinetics can be considered nonlinear kinetics.
Nonlinear kinetics implies deviations in the rate of change in chemical
concentration from first order kinetics in a manner that is dose and /or
time dependent. Dose-dependent nonlinearity can be due to any
carrier mediated process such as metabolism or active transport that
displays transient saturation or cooperativity at high concentrations
(Kwon 2002). Dose-dependent kinetics may be observed as a
18

stimulated or suppressed response function where increases in
chemical concentration result in non additive increases in
concentrations in peripheral compartments in either a synergistic or
capacity limited manner.
3.3

Pharmacodynamics
To this point we have considered the relationship between

administration of chemical into an animal and some of the basic
pharmacokinetic parameters describing the time course of chemical
concentration in biological fluids. Obviously, there are many other
factors, known and unknown that govern the specific “effects” of
chemical exposure on the exposed subject. The study of
Pharmacodynamics (PD) is designed to characterize the effect of the
chemical on the body. If concentration in the plasma and effect site is
in rapid equilibrium, PD models may adequately serve to estimate the
pharmacological effects of chemical in the body. These models are
valuable in capturing the nonlinear aspects of response patterns often
seen in pharmacological experiments and in estimating various
pharmacodynamic parameters used for establishing dosing regimens in
clinical studies (Gabrielsson and Weiner 2000). However,
advancements in the field of pharmacology and toxicology have
included the realization that more often in in vivo experiments,
19

pharmacological effects take time to develop.
Pharmacokinetic/pharmacodynamic (PK/PD) models attempt to link
concentration in the plasma and response to chemical exposure by
linking the pharmacokinetic properties of a chemical to the biological
response observed at the effect site. While direct and simultaneous
measurement of chemical concentration at the effect site and its
pharmacological effect is the most desirable approach to reveal the
true pharmacodynamic profiles of a substance, it is seldom feasible to
measure chemical concentration at the effect site because of limited
accessibility and availability to the site (Kwon, 2002).
3.4

Pharmacokinetic/Pharmacodynamic Modeling
Pharmacokinetic/Pharmacodynamic modeling has become a

common mechanism for elucidating the chemical/effect relationship
when a distributional delay exists or when the system is subject to
time or dose-dependent kinetic and/or dynamic changes. Effect
compartment models are a class of PK/PD models used to account for
differences in concentration between the plasma and effect
compartments by introducing an equilibrium rate constant Keo (Holford
and Sheiner, 1981) (Figure 4).

20

Chemical

Cp(t)

Keo

Ce(t)

Effect

Ke
Figure 4. Illustration of the Effect-Compartment model.
This rate constant Keo eliminates the discrepancies observed between
the plasma and effect compartments resulting in an estimate of
chemical concentration (Ce) in the effect compartment. For example,
an equation used to link a single compartment pharmacokinetic
equation assuming intravenous injection of drug into the central
compartment to a pharmacodynamic model is the following biphasic
kinetic equation.

D Keo
Ce(t ) =
(e − Ket − e − Keot )
V Keo − Ke
Where:
Ce(t)=Concentration in the effect site at time t
D
= dose/volume equivalent to Ce(t=0)
V

Ke = Elimination rate for the central compartment
21

Keo = Distribution rate for the effect compartment
This model is used to account for differences between the central and
effect compartments caused by distributional delay (Kwon 2002). This
function becomes central to the biphasic toxico-diffusion model
discussed in Chapter 5.
Once Ce(t) is derived, effect compartment models can then be used to
estimate pharmacodynamic response. Since observed response can be
represented by either an elevation of the measured effect or an
inhibition of the effect, these effect compartment models are classified
as either Emax (elevated response) or Imax (inhibited response) models.

E (t ) =

E max Ce(t )
EC 50 + Ce(t )

A baseline response E0 can be added to reflect change from baseline.
The term Emax in the equation corresponds to the theoretical maximum
effect while EC50 represents the “half-life” time at which the effect is
half of the maximum response. A power term (n) can be added to the
Emax or Imax models making them sigmoid models (sometimes referred
to as the Hill equation) to represent sigmoid concentration versus
effect curves related to carrier mediated processes such as enzyme
cooperativity (negative or positive) affecting the concentration effect
curve.
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E max Ce n (t )
E (t ) =
EC n 50 + Ce n (t )
Exponents less than 1 increase the initial slope of the curve while an
exponent greater than 1 makes the curve more shallow initially. These
curves converge around the EC50 value and then cross with larger
exponents reaching Emax more quickly while smaller exponents yield
asymptotic values less than Emax. An exponent of 1 reduces the
equation to the standard hyperbolic Emax model.
3.5

Michaelis-Menten Equation
The effect compartment models are based on a well defined

equation developed in the early twentieth century to describe the
fermentation of cane sugar (i.e. sucrose) via hydrolysis into glucose
and fructose. Michaelis and Menten derived an equation built upon
earlier work by Henri and others by carrying out definitive experiments
using the enzyme invertase (Cornish-Bowden 1995). They found that
the rate of the reaction v was dependent on the substrate (sucrose)
concentration ( a ) and limited by the concentration of enzyme in the
reaction. The reaction is described by the equation:
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Initial slope Vmax/Km

Vmaxa
v=
Km + a

Vmax

0.5V

v0
Km

2Km
a

Figure 5. The Michaelis-Menten equation with illustration of the
relationship between substrate concentration (a) and velocity of the
reaction. Km is the concentration of substrate that equaled half the
maximum velocity of the reaction.
Where: Vmax is the limiting rate for the velocity of the reaction and Km
is defined as the Michaelis constant describing the substrate
concentration at which the velocity of the reaction is 1/2 that of Vmax.
Among the many important contributions to the description of this
reaction was the measurement of the initial rate of the reaction
(Vmax/Km) at different sucrose concentrations thereby avoiding
complicating factor such as reverse reaction, product inhibition and
inactivation of the enzyme (Cornish-Bowden, 1995). This equation is
recognized as the fundamental equation of enzyme kinetics and has
been widely used to describe biological processes in areas outside of
its original intent. In pharmacological studies, a relationship described
24

by this type of equation is referred to as having Michaelis-Menten
kinetics.
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Chapter 4
Nonlinear Mixed Effects Models
The HRAMG has advanced the estimation of dose-time-response in
FOB studies by using non-linear mixed effects methods for estimating
response to chemical exposure. These models capture the dosedependent response to chemical exposure while allowing for individual
subject variation in their natural responses to the measurement
instrument in the absence of chemical exposure. Increasingly, these
nonlinear models are evolving to incorporate parameters thought to
describe well known physiological mechanisms governing response.
4.1

Toxico-Diffusion Model

Zhu (2005) used a re-parameterized version of the Michaelis-Menten
equation for the analysis of the FOB data.

f (d , t ) =

B * conc( d , t ) * t
1 + C * conc( d , t ) * t

In this equation

conc ( d , t ) =

d
exp( − K e t )
V
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is dependent on the parameter Ke which can be interpreted as the
elimination rate under intravascular administration (Zhu 2005a). The
parameter V represents the volume of the circulation system or central
compartment. In the toxico diffusion function, V is absorbed into the
parameters B and C in the function.
This function resembles the Michaelis-Menten equation, but with
concentration-dependent coefficients B*conc(d,t) and C*conc(d,t).
The coefficient C can be negative as long as the denominator is
positive within the experimental range (Zhu 2005a). By incorporating
a baseline response (A), the equation describes the change in
response from the initial condition measured prior to exposure
throughout the time course of the study. Assuming that chemical
concentration is directly linked to response, rapid elimination of the
chemical corresponds the function f(d,t) quickly reaching a peak value
at the time of peak effect (TOPE), and returning tobaseline. However,
if the compound remains in the subject’s system, f(d,t) may not return
to the baseline line level, characterizing persistent dose effects.
This function, relying on a one compartment kinetic paradigm,
results in a dose independent TOPE. As t varies from 0 toward infinity,
f(t,d) varies from baseline to a maximum at t = 1 / K e , then back to
baseline, irrespective of dose level. Statistical evidence of neurotoxic
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effects is present when either the coefficient B or C is statistically nonzero.
4.2

Parameter Estimation Methods
Implementation of the toxico-diffusion function represents a

situation where the observed response is predicted based on a
nonlinear function of the estimated parameters in the model. Often in
application of these nonlinear models it is advantageous to incorporate
a random effects parameter in addition to the fixed effects coefficients
to account for natural variation in biological response to the testing
instrument. Thus, random effects represent deviations from the
population average and can enhance parameter estimation and
hypothesis testing procedures by accounting for a source of variation
in the data otherwise subjected to the error term. Given the short
temporal sequences of FOB data, it is rare that the data can
accommodate more than one random effect even if biologically feasible
(Zhu 2005a). Models that incorporate both fixed and random
components are often termed “mixed-effects” models and a detailed
description of their development and implementation can be found in
Pinhiero and Bates (2000). These models generally use maximum
likelihood (ML) methods for parameter estimation. Likelihood functions
for mixed-effects models are generally complex, and closed form
solutions are generally not available. Implementation of ML requires
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iterative numerical procedures such as Newton-Raphson algorithm, the
EM-algorithm, and more often the combinations of them (Lindstrom
and Bates 1988). The model fitting techniques used in this thesis rely
on the Newton-Raphson algorithm.
4.3

Model Selection and Diagnostics
There are several important assumptions associated with mixed

effects models that require validation. Namely, random effects are
assumed to be normally distributed around a mean of zero; the
random effects and the error term are assumed to be uncorrelated,
and the variance is assumed constant across different experimental
conditions. Choosing the most appropriate model to represent the
response observed in the data requires both objective criteria and
sound investigative principle. The Likelihood Ratio Test (LRT) and
Information Criteria (AIC and BIC: Pinhiero and Bates, 2000) are
useful tools for guiding appropriate model selection. Significance
testing using the LRT relies on the Chi-squared distribution (i.e.
2
2(log(L1)-log(L2)) ~ χ p ) , where L1 is likelihood function of the

expanded model and L2 is the existing model, and p is the number of
additional parameters in L1 . While this statistic is readily available in
most computer software packages, the one-sided alternative test may
require weight adjustments in some cases (Zhu, 2005). Another
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restrictive requirement of LRT is that one model must be a sub-model
of the other comparison model. Information Criteria (Akaike, 1973)
are a generalization to the Likelihood Ratio Test. They add to the
likelihood ratio a term to penalize the inclusion of excessive terms in
the model. They do not require one model being a sub-model of the
other, but do require the models follow the same family of
distributions. Akaike’s Information Criteria (AIC) and Bayesian
Information Criteria (BIC) are two popular methods that yield values
for comparing the goodness of fit of two models. The model with the
smaller value of AIC and/or BIC is favored. Investigative principles
include graphical comparisons of the fitted model with the raw data
and residual plots to check for randomness of error terms. These are
helpful tools for selecting the appropriate model in conjunction with
statistical criteria such as the Log-Likelihood Ratio Test (LRT) and
Information Criteria (AIC and BIC). Graphical tools are useful for
visualizing not only the shape of the dose-response but also the
agreement of the predicted and observed responses. Residual plots
check the assumptions of independent, normally distributed errors and
identify potential outlying observations.
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Chapter Five
Expanding the Toxico-Diffusion Function
5.1

Biphasic Toxico Diffusion Function
This thesis generalizes the toxico-diffusion function developed by

Zhu (2005) to estimate the dose-time-response relationship in which a
dose-dependent TOPE is observed. The biphasic toxico-diffusion
function is a modification of the biphasic kinetic equation discussed in
chapter 3 that accounts for discrepancies between the central and
effect compartments in pharmacokinetics. Its foundation is the toxicodiffusion function with the addition of a second exponential term to
achieve a dose-dependent TOPE. The rate of the second exponential
term is dependent on dose as well as time. This second exponential
term forms a complex exponent with the elimination rate either in the
numerator (Equation A) to describe accelerated TOPE or in the
denominator (Equation B) to describe the delayed TOPE often
observed in capacity limited kinetics.

Btd * (exp(− K e * t ) − exp(− K e 0 * dose * t ))
f (t , d ) =
1 + Ctd * exp(− K e * t )
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(A)

f (t , d ) =

Btd * exp( − K e * t )
1 + Ctd * (exp( − K e * t ) − exp( − K e 0 * dose * t ))

(B)

Therefore, these models do require some a priori knowledge of the
dose-response relationship to select the appropriate model to describe
dose dependent TOPE. At some point in the time course of chemical
exposure, assuming Keo >>Ke , the second exponential term of the
biphasic model reduces to zero and the model reverts to the standard
toxico-diffusion function.

f (t , d ) =

Btd * exp(− Ke * t )
1 + Ctd * exp(− Ke * t )

As with the pharmacodynamic models, the biphasic toxicodiffusion models are not intended to be mechanistic in the literal sense
of describing actual pharmacologic or kinetic processes. Rather, here
the purpose of these models is to incorporate pharmacokinetic
concepts into a mathematical model that allows for a dose-related shift
in TOPE that may be related to well known pharmacokinetic processes
such as nonlinear disposition, tissue or protein binding, metabolism or
clearance kinetics observed in pharmacological and toxicological
studies (Gabrielsson and Weiner 2000). Irrespective of the actual
mechanism governing the observed shift in TOPE, these proposed
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models may be useful for describing the FOB data and elucidating
dose-response relationships which exhibit dose-dependent TOPE.
To illustrate the use of the biphasic toxico-diffusion models,
parathion motor activity counts were chosen as the response variable
of interest due to an observed shift in the time of maximal response at
higher dose levels. In the IPCS studies parathion was introduced by
oral gavage in corn oil solution at doses of 0.85, 1.69, 3.38 and 6.75
mg/kg. Parathion is readily absorbed through the digestive tract and
detection in the bloodstream has been reported immediately after oral
administration (INCHEM 2004). Nonlinear binding of the toxic
parathion metabolite, paraoxon, has been reported for red blood cells
(with supra-linear dose-response) and brain tissue (with a sub-linear
dose-response) (Vogel et al. 2002). Kramer et al. (2002) used a three
compartment model to describe the pharmacokinetics of Methyl
Parathion but failed to elucidate the pharmacodynamic properties
associated with this hazardous organophosphorus pesticide. For the
model described in this thesis to be related to physiological processes,
bioavailability is assumed to be 100% and absorption from the
gastrointestinal tract is assumed to be nearly instantaneous.
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5.2

Parathion Activity Counts
Examination of the raw data plots reveal the relationship between

dose, time and activity counts observed after a single exposure to
parathion (Figure 6). These grouped data plots are constructed such
that the control group is the first graph (starting on the left), followed
by panels of increasing dose to the right. The x axis is in log scale for
display purposes only.

Figure 6. Observed response in activity counts of rats subjected
to acute parathion exposure. Note: Panels are arranged in an
increasing order of dose (0, 0.85, 1.68, 3.38, 6.75) from left to
right.
It is apparent that dose increases resulted in changes of the response
trajectories (Table 1). The two highest dose groups (3.38mg/kg and
6.75 mg/kg ) appeared to have vastly lower activity counts than the
lower dose groups. The observed TOPE associated with the higher dose
groups was 2H compared with a TOPE at 24H for the controls and the
lowest dose group.
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Table 1. Dose group average activity counts for motor activity counts
after acute parathion exposure with standard deviation in parenthesis
Time

Dose
0

0
323.6 (51.3)

2
225.6 (72.1)

24
180.2 (71.4)

168
222.3 (70.0)

0.85

316.0 (53.2)

217.8 (83.9)

178.9 (76.0)

257.5 (60.5)

1.69

291.9 (37.5)

207.6 (44.5)

185.5 (59.9)

232.5 (95.8)

3.38

336.2 (57.8)

139.6 (99.2)

144.0 (42.4)

224.9 (77.9)

6.75

296.2 (64.1)

15.9 (14.7)

93.6 (49.9)

201.7 (67.7)

These aspects of the observed data suggested that the parathion
activity count data may allow for an application of the biphasic
numerator model. Therefore, the biphasic numerator model (equation
1) was applied the parathion motor activity counts to describe the
apparent acceleration of TOPE observed in the data.
5.3

Fitted Response
The fitted biphasic model predicted a decline in activity counts

after exposure to parathion, and the predicted trend resembles the
observed pattern. However, only the intercept A and the rate
parameter Ke were statistically significant, the slope factors B and C
and Keo are insignificant (Table 2). A large amount of variation in the
data was attributable to the between rat variation at baseline and was
accounted for by a random effect for baseline activity count. The
random effects had a standard deviation 35.9, about 54% of residual
standard deviation (Table 2).
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Table 2. Summary of biphasic model fit to parathion activity counts
Parameter
A
B
C
Ke
Keo
Random
Effects

Estimate
258.0129
-72.3701
0.2265
0.1400
0.3198
Intercept

Standard
Error
7.91744
83.48372
0.35207
0.03561
0.21072
Residual

35.93553

65.08784

DF

t-value

146
146
146
146
146

32.588
-0.867
0.643
3.931
1.518

p-value
<.0001
0.387
0.521
0.0001
0.131

The fitted biphasic model appeared to be a reasonable fit the observed
data. The fitted dose-response pattern resembles the observed data in
aspects of TOPE and magnitude of response changes.

Figure 7. Fitted response of biphasic numerator model for rats
subjected to acute parathion exposure.

Evidence of a good fit of the model to the data comes through
examination of the residual plots. Residual plots express the difference
between the observed and predicted responses, termed “error”. An
assumption of nonlinear mixed effects models is that the errors are
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independent and normally distributed. Standardized residual plots for
the parathion activity counts (Figure 8) suggest that the errors are

Standardized residuals

centered on a mean of zero and fairly randomly distributed.

0

dose
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0

dose

dose

50 100 150 200 250 300
dose

dose

3
2
1
0
-1
-2
0

50 100 150 200 250 300
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0

50 100 150 200 250 300

Fitted values

Figure 8. Residual plots of biphasic model for rats subjected
to acute parathion exposure. Note: Panels are arranged in
an increasing order of dose (0, 0.85, 1.68, 3.38, 6.75) from
left to right.

The NLME models further assume that the errors are constant across
dose group while often in biological settings the variance will increase
in proportion to the mean response. When there is evidence of nonconstant standard deviation, NMLE can incorporate a separate
standard deviation to each dose group and verify the resulting model
improvement using the Likelihood Ratio Test (LRT). The addition of
dose group specific standard deviations to compensate for
heteroscedascity did not significantly improve the model fit according
to the likelihood ratio test (log(L2)-log(L1)) value of 7.28 and a
corresponding p-value of 0.122. This suggests that a constant
standard deviation across dose groups is acceptable.
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5.4

Dose-Dependent TOPE
The fitted model also reveals different times of peak effect

determined by dose level (Figure 9): the higher dose groups clearly
had an accelerated TOPE. The TOPE varied from 11.5 hours for the
lowest dose group (0.85mg/kg) to 7.3 and 7.1 hours for the

250

3.38mg/kg and 6.75mg/kg dose groups, respectively.
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Figure 9. Dose specific trajectories for biphasic model on rats
subjected to acute parathion exposure.
The fitted model can also be examined for each subject after
accounting for the random effect at baseline (Figure 10). Indeed, the
predicted model appears to capture individual (red) deviation when
compared to the population average (blue).
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Figure 10. Individual specific trajectories for biphasic model on
rats subjected to acute parathion exposure.
The biphasic model can be viewed as a generalization of the toxicodiffusion model to allow for a dose-dependent TOPE. Given that these
models have this hierarchical structure, Information Criteria and the
Log Likelihood Ratio test were used to test for improvement in the fit
of the biphasic model relative to the fit of the toxico diffusion model
(Figure 11). Both Information Criteria and the Log Likelihood Ratio test
suggest a significant improvement of the biphasic model overall (Table
3). Despite the fact that the dose-dependent coefficients (B and C)
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and the second kinetic coefficient Keo in the biphasic model are
statistically insignificant, due perhaps to limited number of data points
(in time or subjects) in the experiment, the biphasic model is
attractive because it permits dose-varying TOPE as indicated by the
motor activity count data. Further, the magnitude of response
predicted by the biphasic model was dramatically different between
the two models with the toxico-diffusion model predicting peak
response (in this case lowest activity count) of 100 at the highest dose
level while the biphasic model predicted a peak response (lowest
activity count) of three; the true response observed in the data (see
figure 6). Correctly predicting the magnitude of peak effect is
important as the peak effect could have dramatic implications on
benchmark dose estimation. On the grounds of toxicology, it is
generally accepted that the TOPE is less likely to be a constant. With
only a limited number of time points (4 in the case of motor activity
counts) spread over a wide range, however, variance in TOPE is less
likely to be detectable from the FOB data. Therefore, verification of a
true dose-related TOPE is difficult because the statistical power in
detecting the variation in observed TOPE from standard FOB assay
data is low.
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Figure 11. Predicted response to parathion by the toxico-diffusion
model.
Table 3. Results of log likelihood (LL) ratio test comparing the toxicodiffusion (TD) and Biphasic Numerator (BNM) models.
Model
TD
BNM

DF
AIC
BIC
LL
6
2297.751 2317.541 -1142.876
7
2291.730 2314.818 -1138.865

Chi Sq.

Pr>Chi.Sq

8.021

0.0046

The analysis thus far has demonstrated that FOB assays using
scarcely spaced experimental time points will likely fail to generate
sufficient data for dose-response modeling especially when dose
varying TOPE’s are considered. The next chapter focuses on
considering FOB designs that may provide enough information about
the true dose-response necessary to capture dose-dependent response
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patterns of neuro-toxicological effects, particularly dose-dependent
time of peak effects, in a valid and reliable manner. In the next
chapter, computer simulation is used to explore the most effective FOB
design protocols to predicted dose-dependent TOPE using the biphasic
toxico diffusion model.

42

Chapter 6
Simulation
6.1 Simulation Rationale
While the biphasic toxico-diffusion model appeared
advantageous relative to the toxico diffusion model in permitting dosedependent TOPE, the parathion motor activity count data leaves some
uncertainty about the model as the parameter estimates for the B, C
and Keo were statistically insignificant. This lack of statistical power
seemed to result from insufficient data generated under the current
FOB design. Specifically, the sparse spacing of experimental testing
times is believed to provide insufficient data for model
parameterization. Therefore, Monte Carlo simulation was adopted to
investigate the design protocols necessary to recover the key
characteristics of dose-dependent response along the time course as
predicted by the biphasic model. The primary objective of the
simulation was to investigate the benefits of considering alternative
time spacing and/or adding additional experimental testing times
and/or experimental subjects to the FOB design to recover the key
characteristics of the biphasic model with regard to parameter
43

estimation. Assuming that the biphasic model represents the true
underlying response of rat motor activity to acute parathion exposure,
we could construct a dataset through simulation that contained the
underlying response at a sequence of possible testing times in addition
to the experimental times in the FOB study. We could also control the
number of subjects in each dose group. The simulation experiments
then allowed us to evaluate, empirically, the efficiency of designs with
various locations and frequencies of testing times as well as with
additional subjects needed for the biphasic toxico-diffusion model to
capture the dose and time dependent characteristics of the “true”
response.
6.2 Simulation Methods
We obtained the parameter estimates from fitting the biphasic
model to the motor activity count data of rats exposed to parathion.
These estimates were then used as the population (“true”) parameters
in the biphasic function to define the “true” dose-response model.
Dose levels remained the same as those used in the original parathion
experiment. Within the content of simulation, the fitted model
represents the true underlying mean response to parathion, and the
random effects and random errors govern variation among rats in a
given population. Generating simulation datasets required several
steps:
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Step 1. Generate the mean underlying dose-time-response curve using
the biphasic model (with the parameter estimates in Table 1)
at selected dose and time levels. This step results in average
response specific to the given dose and time involved in the
designed experiment (Figure 12).
Step 2. Add random effects. To account for each subject’s deviation
from the average score at baseline, random effects were
generated for each subject using a normal distribution,
N(0, σ D), where the standard deviation ( σ D ) was taken from
the estimate (35.94) of the fitted biphasic response model.
The random effects were added to the mean response at every
dose-time point in the form of the random intercepts. In the
present simulation there was one random effect for each rat.
Step 3. Add random errors. Random errors were generated for each
individual observation from a normal distribution N(0, σ ε ) and
added to the mean response to represent measurement
variation ( σ ε = 65.09) around the mean response.
Step 4. Repeat Steps 1-3 n times to generate data of n rats per dose
group. This process generates one simulated experiment.
Step 5. Repeat Step 4 one thousand times to generate 1000
replications of the experiment.
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Based on this simulation protocol, we generated motor activity scores
for n rats in each dose group at a sequence of desired testing times.
We simulated responses at each of the time points used in the original
study (i.e. 0,2,24,168) as well as additional points in 4 hour intervals
between times 4 and 24 (i.e. hours 4, 8,12, 16,20). In this way we
had information at a multitude of testing times around the time of
peak effect, which allowed us to identify effective designs for
recovering key characteristics of the biphasic model.
The purpose of analyzing these simulated experiments was to
assess the efficiency of these experiments with respect to recovering
the “true” underlying dose-response information, specifically dosedependent TOPE, with a high level of statistical certainty (power).
Thus, we first considered two groups of simulation experiments, 4time point designs and 5-time point designs with ten subjects per dose
group. While a larger number of time points are statistically desirable,
designs with 4-5 time points are more practical and more closely
follow the EPA neurotoxicity risk guideline (USEPA, 1998). Intuitively,
a time point in the neighborhood of the true TOPE would provide the
most relevant information on the TOPE. Therefore, in the 4-point
design, we retained three time points, 0, 24, and 168 hours from the
original design protocol and let the 2nd time point vary between 2 h
and 24 h. These design variations aim at assessing the efficiency of
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the original FOB experimental design. In the 5-point design, an
additional time point between 4 and 24 hour was added to the original
FOB experiment.
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Figure 12. Theoretical “true” dose-dependent biphasic model
response between 0 hours and 24 hours. Candidate
experimental testing times used for simulation are indicated by
the broken vertical lines
In addition to the 4-point and 5-point designs, we also
considered designs with 6, 7, 8, or even 9 time points for the purpose
of statistical dose-response modeling. These simulated experiments
helped illustrate the relative gain of using additional points in
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increasing statistical power or gaining information on the doseresponse. In order to see the effects of sample size on statistical
power, we also considered using more subjects (i.e. 20, 30) at each
dose level under the 4 and 5- time point designs. Note there are three
5-point designs that did not use 2 hours as an experimental point but
rather contain 2 testing times between 4 and 12 hours as well as at
hours 0, 24 and 168.
One thousand data replicates of each of the 35 design trials
listed in Table 4 were generated and analyzed to evaluate each design.
Efficiency of the design was evaluated in the following ways:
1) The convergence rate - the number of fits on the biphasic
numerator model that reached successful model convergence out
of the 1000 replicate trials.
2) Statistical power: The percentage of times the t statistic for each
parameter exceeded its 95th-percentile (p-value less than 0.05,
or type I error at 0.05).
3) Bias = ( Σ ( φ i − φ )/n): The difference between the true model

ˆ

parameter and the average of 1000 replications of the parameter
estimate.
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4) Mean Squared Error = ( Σ ( φ i − φ )/n)2+ σ 2: The Bias squared + the

ˆ

sample variance of the 1000 replications of the parameter
estimate.
5) The Bias and MSE of the Time of Peak Effect (TOPE).

These statistical criteria were used to compare the designs and identify
the more efficient designs with respect to dose-response modeling of
the biphasic toxico-diffusion model. It should be noted that the
assessment of power for any parameter estimate precludes the
situation that the parameter is not meaningful both biologically and
mathematically. This is because any parameter can be imposed and
signified statistically with a sufficiently large dataset. However, the
case of biphasic model indeed precludes the possibility of statistical
manifestation. While found to be statistically insignificant in the
original model fit, the model parameters have inherent importance in
the model function to describe the response (e.g. initial rate of change
in response, “half-peak” effect dose, and dose dependence in TOPE).
Comparison with different models suggested the magnitude of the
parameter estimates were non-trivial, but the design was
underpowered to ascertain the value. Within the context of simulation,
the scenario of such a statistical manifestation can be plainly excluded
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because data were generated from the biphasic model and all involved
parameters are mathematical quantities in existence.
Table 4. Simulated experimental FOB designs using 10, 20, and 30
subjects per dose group. Experimental testing times were added
between 4 and 20 hours.
Testing Times
(Hours)
4 time-point
designs
0,2,24,168
0,4,24,168
0,8,24,168
0,12,24,168
0,16,24,168
5 time-point
designs
0,2,4,24,168
0,2,8,24,168
0,2,12,24,168
0,2,16,24,168
0,2,20,24,168
Alt. 5 time-point
designs
0,4,12,24,168
0,8,12,24,168
0,4,8,24,168
Extended time-point
designs
0,2,4,12,24,168
0,2,8,12,24,168
0,2,4,8,12,24,168
0,4,8,12,16,24,168
0,2,4,8,12,16,24,168
0,2,4,8,12,16,20,24,168

Number of
Subjects

Number of
Time
Points

10
10
10
10
10

4
4
4
4
4

10,20,30
10,20,30
10,20,30
10,20,30
10,20,30

5
5
5
5
5

10,20,30
10,20,30
10,20,30

5
5
5

10
10
10
10
10
10

6
6
7
7
8
9
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6.3

Simulation Results

6.3.1 Four Time Point Designs: Ten Subjects
In the 4-time point design, only the 2nd point differs from the
original FOB experiment protocol. The 2nd time point varied from 2 to
16 hours, the results showed pronounced effect on the power of
detecting the parameter Keo (Table 5). When the second time point
was chosen to be hours 8 or 12, the statistical power for the non-zero
Keo improved from 45 % to approximately 80%. However, for the
parameters B and C the power of detecting a non-zero value remained
low, ranging from 0.1% to 15.5%. The convergence rate in fitting the
biphasic model decreased markedly as the second testing time moved
past 12 hours. For example, the convergence was only about 72.9% at
16 hours, suggesting the data did not provide adequate information to
even fit the model. Note that the shaded row indicates the design that
appeared to be most beneficial for recovering the true model response.
Table 5. Summary of simulated design trials with 10 subjects per dose
group and 4 testing times.
4 Point Designs
Time Points
0,2,24,168
0,4,24,168
0,8,24,168
0,12,24,168
0,16,24,168

PARAMETER
Power (% p<0.05) (average p value of t-statistic)
B
C
Keo
Convergence
(%)
15.5(0.329)
0.0(0.466)
45.5(0.118)
94.1
11.5(0.309)
0.0(0.392)
69.1(0.068)
93.1
5.7(0.259)
0.0(0.329)
81.6(0.057)
88.5
1.2(0.271)
0.0(0.341)
80.5(0.063)
82.6
0.1(0.331)
0.0(0.398)
75.7(0.091)
72.9

Cont’d next page
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Table 5 Cont’d
1) 2nd testing time was selected at various times from 2-16 hours and effects on
power and statistical significance examined.
2) Numbers in columns 2, 3, and 4 indicate the percent of time a p value <0.05
was observed while numbers in parentheses represent the average p_value
based on 1000 replications.
3) The first row (design 0,2,24,168) is the true FOB design on which this
simulation was based

Bias and MSE were also used to evaluate an efficient design for
parameter estimation using the biphasic model. Bias represents the
average difference in the location of the parameter estimate while MSE
represents the imprecision of that estimate across the 1000
replications of each simulated experimental design. Consistent with the
results of the power analysis, bias and MSE for the Keo parameter were
the smallest at 8 hours and therefore represented the best choice of
testing times within this group of designs (Table 6) for this endpoint.
However, the bias and MSE in parameters B and C appeared to be the
smallest when the second testing time was at 16 hours. Convergence
decreased markedly for designs with the hour 16 being a testing time,
which may have affected the MSE for this design by eliminating some
of the larger variations in the parameter estimates. The MSE for the
hour 8 testing time was not markedly different from the hour 16
design for parameters B, C and Ke and had a higher convergence rate.
This lends further support for the 0,8,24,168 design as the best choice
among the 4 time point designs. In general, the MSE was so large for
the B parameter that it should be no surprise that statistical
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significance was not achieved for this parameter in any of these
designs. In view of the results in Table 6, one can conclude that 4point designs did not have the statistical power to reliably detect the
appropriate biphasic model for this endpoint.
Table 6. Bias and MSE for each parameter of interest for the 4 time
point designs with 10 subjects.
Design

Bias_B

Bias_C

Bias_Ke

Bias_Keo

0,2,24,168

-1.59E+03

8.91E+00

6.05E-03

7.47E-02

0,4,24,168

-1.76E+04

9.81E+01

1.12E-02

2.88E-02

0,8,24,168

-1.33E+02

6.59E-01

1.12E-03

-1.89E-02

0,12,24,168

-1.29E+02

6.48E-01

-1.09E-02

-6.43E-02

0,16,24,168

-9.87E+01

5.29E-01

-2.80E-02

-1.10E-01

MSE_B

MSE_C

MSE_Ke

MSE_Keo

0,2,24,168

6.55E+08

2.25E+04

3.03E-03

8.81E-02

0,4,24,168

7.94E+10

2.50E+06

4.34E-03

3.39E-02

0,8,24,168

3.53E+05

8.69E+00

3.16E-03

2.10E-02

0,12,24,168

1.63E+06

3.76E+01

4.52E-03

2.35E-02

01624168

3.08E+05

8.52E+00

6.59E-03

3.39E-02

Design

6.3.2

Five Time Point Designs: Ten Subjects
Due to the lack of statistical power in parameter estimation in

the 4-time point designs, we examined the benefits of adding an
additional testing time. We retained the 4-time points of the FOB
design and allocated an additional testing time between 4 and 20
hours. In a second situation of 5-point designs we also removed the
hour 2 time point and added 2 time points between 4 and 12 hours to
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see if time points closer to the true TOPE would increase the statistical
power.
The 5-point designs generally improved the power for all
parameters of interest (Table 7). The average p value for Keo reached
a level below 0.05, and the power improved to above 80% for designs
with the additional testing times between 4 and 12 hours. The
improvement in power was less pronounced when the additional point
was beyond 16 hours. For parameter C, the power remained at a low
level of less than 10%. For the B parameter, the power reached a
highest level of 28% when the added time point was at 16 hours, and
stayed at a comparable level within the time range of 8 to 20 hours.

Table 7. Summary of simulated design trials on FOB parathion data
with 10 subjects per dose group and 5 testing times.
PARAMETER
% p<=0.05 (mean)

5 Point Designs
Time Points
0, 2, 4, 24, 168
0, 2, 8, 24, 168
0, 2, 12, 24, 168
0 ,2, 16, 24, 168
0, 2, 20, 24, 168
Alternate 5 point
designs
0, 4,12, 24,168
0, 8,12, 24,168
0, 4, 8, 24,168

B

C

Keo

21.2(0.220)
24.5(0.147)
24.5(0.147)
27.7(0.158)
25.8(0.198)

2.0(0.303)
9.8(0.213)
9.8(0.213)
7.4(0.233)
2.6(0.292)

80.9(0.030)
82.4(0.030)
82.0(0.033)
73.5(0.047)
58.3(0.072)

Convergence
(%)
97.3
99.0
98.4
97.2
96.4

22.0(0.160)
17.6(0.144)
21.2(0.169)

7.8(0.222)
1.6(0.204)
5.4(0.232)

87.4(0.033)
89.6(0.032)
90.4(0.024)

95.2
91.3
96.4

1) The experimental testing time (3rd testing time) was adjusted by 4 hour
intervals and effects on power examined.
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2) Numbers in columns 2, 3, and 4 indicate the percent of time a p value <0.05
was observed while numbers in parenthesis represent the average p_value
based on 1000 replications.
3) The true design on which this simulation was based included actual testing
times of 0,2,24, and 168 hours.

Interestingly, dropping the hour 2 testing time and adding two testing
times between 4-12 hours had little effect on the statistical power
though in one case (0,4,8,24,168) a large bias was introduced (Table
8). The bias for B, C, and Ke was smallest with the design of
0,8,12,24,168 hours while the bias of Keo was the smallest with the
0,4,8,24,168 design. The MSE was smallest with the 0,8,12,24,168
design for three of the four parameters of interest.
Table 8. Bias and MSE for each parameter of interest for the 10
subject, 5 time point design.
Design

Bias_B

Bias_C

Bias_Ke

Bias_Keo

0,2,4,24,168
0,2,8,24,168
0,2,12,24,168
0,2,16,24,168
0,2,20,24,168

-3.50E+02
-1.33E+02
-1.33E+02
-1.23E+02
-1.17E+02

1.86E+00
6.95E-01
6.93E-01
6.41E-01
6.05E-01

1.00E-02
9.53E-03
8.68E-03
5.04E-03
3.89E-03

4.11E-02
4.80E-02
4.56E-02
5.52E-02
7.47E-02

0,4,12,24,168
0,8,12,24,168
0,4,8,24,168

-5.71E+02
-6.99E+01
-1.47E+08

3.11E+00
3.58E-01
8.49E+05

5.77E-03
-4.18E-04
8.97E-03

1.96E-02
-2.22E-02
1.56E-02

MSE_B

MSE_C

MSE_Ke

MSE_Keo

0,2,4,24,168
0,2,8,24,168
0,2,12,24,168
0,2,16,24,168
0,2,20,24,168

3.39E+07
1.28E+06
1.28E+06
2.94E+06
3.55E+05

1.06E+03
3.70E+01
3.70E+01
8.05E+01
9.73E+00

1.81E-03
9.67E-04
1.08E-03
1.31E-03
1.67E-03

3.43E-02
5.17E-02
5.22E-02
5.20E-02
7.02E-02

0,4,12,24,168
0,8,12,24,168
0,4,8,24,168

2.21E+08
1.68E+05
2.16E+19

6.78E+03
4.05E+00
7.22E+14

1.91E-03
2.40E-03
2.36E-03

3.16E-02
1.91E-02
2.11E-02

Design
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6.3.3 Designs with Six – Nine Time Points.
The results of the 5-time point designs begs the question “How
many testing times will be enough to achieve required statistical power
for the B and C parameters and acceptable bias and MSE?”. In an
attempt to answer this question, we increased the number of testing
times from 5, to between 6 to 9 points, by adding additional points
between 0 and 24 hours. As the number of testing times increased,
the statistical power improved but even with 9 time points, the
statistical power was still below 70% for B and 37% for C (Table 9). It
is clear that as the number of time points increases, the power
increases generally. Furthermore, fixing the number of time points
yielded some data more informative than others.
Table 9. Summary of simulated experiments with six to nine points
and 10 subjects per dose group.
PARAMETER
% p<=0.05 (mean)

Time Points
(Extended time point
designs)

B

C

Keo

0,2,4,12,24,168
0,2,8,12,24,168
0,4,8,12,24,168
0,2,4,8,12,24,168
0,4,8,12,16,24,168
0,2,4,8,12,16,24,168
0,2,4,8,12,16,20,24,168

33.5(0.113)
43.7(0.084)
34.8(0.101)
47.4(0.073)
49.0(0.070)
62.6(0.049)
68.3(0.043)

13.2(0.171)
16.1(0.133)
12.6(0.152)
19.7(0.117)
18.8(0.114)
31.0(0.086)
36.6(0.077)

95.4(0.010)
93.2(0.017)
93.5(0.019)
97.3(0.006)
93.9(0.014)
98.0(0.004)
98.0(0.005)

Convergence
(%)
98.8
98.8
96.9
99.2
96.8
99.2
99.0

1) Two experimental testing times were added (3rd and 4th testing times) and
adjusted by 4 hour intervals and effects on power examined.
2) Numbers in columns 2, 3, and 4 indicate the percent of time a p value <0.05
was observed while numbers in parenthesis represent the average p_value
based on 1000 replications.
3) The true design on which this simulation was based included actual testing
times of 0,2,24, and 168 hours.

56

The bias and MSE were generally reduced as the number of testing
times increased for parameters B, C, and Ke, although the smallest
bias in Keo was attained with the 7 time point design of
0,4,8,12,24,168 (Table 10) and smallest MSE for Keo was associated
with the 8 time point design 0,2,4,8,12,16,24,168. Even with the 9
time point design, the coefficient of variation for parameter B was still
45% of the average.
Table 10. Bias and MSE for Simulated Experiments with 6 and 9 time
points and 10 subjects
Design

Bias.B

Bias.C

Bias.Ke

Bias.Keo

0,4,8,12,24,168
0,4,8,12,16,24,168
0,2,4,8,12,24,168
0,2,4,8,12,16,24,168
0,2,4,8,12,16,20,24,
168

-6.00E+01
-7.32E+01
-8.85E+01
-4.94E+01

3.06E-01
3.96E-01
4.62E-01
2.58E-01

6.42E-03
4.63E-03
9.12E-03
7.59E-03

1.37E-02
1.15E-02
1.76E-02
1.77E-02

-3.99E+01

2.10E-01

6.37E-03

2.14E-02

MSE.B

MSE.C

MSE.Ke

MSE.Keo

3.46E+04
8.57E+05
1.29E+06
7.05E+04

8.02E-01
2.74E+01
3.77E+01
1.97E+00

1.22E-03
1.18E-03
7.05E-04
5.94E-04

2.24E-02
1.71E-02
1.69E-02
1.44E-02

1.09E+04

2.71E-01

5.82E-04

1.84E-02

Design
0,4,8,12,24,168
0,4,8,12,16,24,168
0,2,4,8,12,24,168
0,2,4,8,12,16,24,168
0,2,4,8,12,16,20,24,
168

6.3.4 Designs with Increasing Number of Subjects
While the simulations have clearly demonstrated that increasing
the number of time points and selecting “informative” time points can
generally improve the efficiency of an experiment, there remains a
considerable amount of MSE, particularly associated with parameter B.
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This suggests that while selection of time points is essential in
soliciting information on the shape of dose-response, to reduce
variation increasing the number of subjects may also be important.
Therefore, a second simulation was performed using the 5-point
experiments with 20 or 30 subjects per dose group.

6.3.5 Five time point designs with twenty subjects
Adding 10 additional subjects to each dose group resulted in
pronounced improvement in statistical power for estimating the
parameters. It is seen from Table 11 that the power for Keo was
consistently above 95% among all experiments, and the power for
parameters B and C reached 77% and 44% respectively under the
design of 0,8,12,24,168 hours.
Table 11. Summary of simulated design trials on FOB Parathion data
with 20 subjects per dose group and 5 testing times.
PARAMETER

Time Points
5 Point Design
(20 subjects per
dose group)

% p<0.05 (average p value)
B

C

Keo

0,2,4,24,168
0,2,8,24,168
0,2,12,24,168
0,2,16,24,168
0,2,20,24,168

33.0 (0.104)
63.8 (0.049)
70.3 (0.041)
61.5 (0.053)
47.7(0.079)

10.1(0.168)
24.2 (0.089)
29.2 (0.081)
25.3 (0.100)
18.2(0.142)

98.4 (0.004)
98.6 (0.003)
96.9 (0.006)
96.8 (0.009)
93.7(0.016)

Convergence
(%)
99.4
99.8
99.5
99.6
99.0

0,4,12,24,168
0,8,12,24,168
0,4,8,24, 168

64.3(0.048)
76.9 (0.036)
57.0(0.056)

28.3 (0.086)
43.7 (0.067)
25.5 (0.097)

98.2 (0.004)
96.4 (0.011)
99.4 (0.002)

98.6
97.0
98.7

Cont’d next page
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Table 10 Cont’d

1) The experimental testing time (3rd testing time) was adjusted and effects on
power examined.
2) Numbers in columns 2,3, and 4 indicate the percent of time a p value <0.05
was observed while numbers in parenthesis represent the average p_value
based on 1000 replications.
3) The true design on which this simulation was based included actual testing
times of 0,2,24, and 168 hours.

Under these 20 subject experiments, bias associated with the
estimates of B, and C was rather invariant while bias in Ke was
minimized with the 0, 2, 20, 24, 168 design and Keo was minimized
with the 0, 2, 8, 24, 168 design. The MSE for the 20 subject designs
was generally reduced by at least an order of magnitude compared
with the same designs of half the number of subjects. The smallest
MSE was achieved with designs where the third time was located at
either 8 or 12 hours (Table 12). The best statistical properties of the
Keo parameter again was achieved under a slightly different design
with time points of 0, 8, 12, 24, 168. While increasing the number of
subjects per dose group did not reduce bias, it dramatically reduced
the uncertainty of the statistical quantities as measured by MSE.
Because of the disparity of statistical power in estimating the
parameters, we further investigated the case of 30 subjects per dose
group.
Table 12. Bias and MSE for each parameter of interest for the 20
subject, 5 time point design.
Design

Bias.B

0,2,4,24,168
-5.39E+01
0,2,8,24,168
-3.96E+01
Cont’d next page

Bias.C

Bias.Ke

Bias.Keo

2.74E-01
2.08E-01

8.34E-03
7.67E-03

2.03E-02
1.34E-02
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Table 12 Cont’d
0,2,12,24,168
0,2,16,24,168
0,2,20,24,168
0,4,12,24,168
0,8,12,24,168
0,4,8,24,168
Design

-3.20E+01
-3.17E+01
-3.17E+01
-3.53E+01
-3.35E+01
-4.29E+01
MSE.B

1.73E-01
1.70E-01
1.68E-01
1.90E-01
1.83E-01
2.26E-01
MSE.C

5.46E-03
4.83E-03
2.96E-03
5.41E-03
3.29E-03
7.11E-03
MSE.Ke

2.61E-02
3.66E-02
4.94E-02
9.84E-03
-2.88E-03
3.03E-03
MSE.Keo

0,2,4,24,168
0,2,8,24,168
0,2,12,24,168
0,2,16,24,168
0,2,20,24,168

1.61E+04
6.43E+03
5.18E+03
6.44E+03
9.26E+03

3.65E-01
1.46E-01
1.21E-01
1.47E-01
2.08E-01

6.46E-04
3.81E-04
3.82E-04
4.22E-04
5.88E-04

1.30E-02
1.29E-02
2.05E-02
2.79E-02
3.21E-02

0,4,12,24,168
0,8,12,24,168
0,4,8,24,168

5.68E+03
8.01E+03
8.10E+03

1.29E-01
1.80E-01
1.86E-01

6.07E-04
9.13E-04
6.52E-04

1.00E-02
8.36E-03
6.69E-03

6.3.6 Five-Time Point Designs: Thirty Subjects
A final simulation was conducted on the parathion data using 30
subjects per dose group. As expected, adding an additional 20 subjects
to the original design resulted in greater convergence rates and nearly
satisfactory statistical power for all parameters. Table 13 clearly shows
that the design of 0, 8,12,24,168 yielded the largest power for
parameters B and C. We further note that the power of C is
particularly sensitive to design whereas B, Ke, and Keo are less so.
Table 13. Summary of simulated design trials on FOB Parathion data
with 30 subjects per dose group and 5 testing times.
PARAMETER
% p<0.05 (mean)

Time Points
5 Point Design
(30 subjects per dose
group)

0,2,4,24,168
0,2,8,24,168
0,2,12,24,168
Cont’d next page

B

C

Keo

50.5(0.057)
93.0(0.016)
94.6(0.014)

21.1(0.103)
73.4(0.038)
78.2(0.035)

100(<0.001)
99.8(<0.001)
99.9(0.001)
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Convergence
(%)
100
99.9
100

Table 13 Cont’d
0,2,16,24,168
0,2,20,24,168
0,4,12,24,168
0,8,12,24,168
0,4,8,24,168

89.4(0.021)
70.4(0.039)
92.7(0.016)
97.8(0.009)
88.5 (0.021)

56.7(0.049)
35.3(0.081)
73.0(0.037)
92.0(0.023)
67.3 (0.043)

99.8(0.002)
99.5(0.003)
97.8(0.002)
97.0(0.004)
99.6 (<0.001)

99.9
99.9
98.0
98.5
99.9

1) The experimental testing time (3rd testing time) was adjusted by 4 hour
intervals and effects on power examined.
2) Numbers in columns 2, 3, and 4 indicate the percent of time a p value <0.05
was observed while numbers in parenthesis represent the average p_value
based on 1000 replications.
3) The true design on which this simulation was based included actual testing
times of 0,2,24, and 168 hours

We expect that adding additional subjects to the experimental
design will reduce the MSE but that the relative performance of the
designs will remain consistent with the results under 20 subjects.
Indeed, as with the twenty-subject experiments, the 0,2,20,24,168
design with 30 subjects retained the smallest bias for parameters B, C,
and Ke while the 0,8,12,24,168 design has the smallest bias for Keo
(Table 14). It is intriguing that, except for Ke, bias was reduced under
the 30-subject designs, although the magnitude was small. A plausible
explanation is the replication size (1000) of the simulation may not be
sufficiently large to stabilize the variation of the parameter estimators.
The design which attained the smallest MSE for Ke was consistent
with the 20-subject design (i.e. 0, 2, 12, 24, 168). However, the MSE
for parameters B and C and Keo was slightly different (though the
same order of magnitude) from the results using 20 subjects.
Specifically, the smallest MSE for these parameters occurred with the
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0, 8, 12, 24, 168 design under 30 subjects. This discrepancy may be
attributed to (1) reduction in bias and (2) non-convergence in
simulations. Reduction in bias may change the expected relationship
between MSEs’ of the 20- and 30-subject designs. When a simulated
experiment resulted in non-convergence in model fitting, the
underlying extreme value was excluded in the computation of bias and
MSE. Since the non-convergence rate was slightly higher under the
20-subject design, it is possible that the designs with the smallest
observed MSE would no longer be the one if the convergence rate
improved. Finally, there is a possibility that chance alone was
responsible for the inconsistent MSE. If this is the reason, increasing
the size of simulation replication would be helpful. Despite this artifact
of inconsistency, it is clear that including testing times around the true
TOPE was most beneficial in recovering the true dose-response profile.
Table 14. Bias and MSE for each parameter of interest for the 30
subject, 5 time point design.
Design
0,2,4,24,168
0,2,8,24,168
0,2,12,24,168
0,2,16,24,168
0,2,20,24,168
0,4,12,24,168
0,8,12,24,168
0,4,8,24,168
Design
0,2,4,24,168
0,2,8,24,168
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Bias.B

Bias.C

Bias.Ke

Bias.Keo

-4.70E+01
-3.21E+01
-2.71E+01
-2.55E+01
-2.53E+01
-2.80E+01
-2.54E+01
-4.29E+01

2.41E-01
1.72E-01
1.48E-01
1.39E-01
1.37E-01
1.55E-01
1.43E-01
2.26E-01

8.87E-03
6.84E-03
5.63E-03
4.77E-03
3.69E-03
3.50E-03
3.74E-03
7.11E-03

6.82E-03
2.15E-03
8.42E-03
1.75E-02
2.99E-02
5.85E-03
-1.21E-03
3.03E-03

MSE.B

MSE.C

MSE.Ke

MSE.Keo

1.01E+04
3.44E+03

2.30E-01
7.98E-02

3.99E-04
2.46E-04

4.37E-03
4.03E-03
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0,2,12,24,168
0,2,16,24,168
0,2,20,24,168
0,4,12,24,168
0,8,12,24,168
0,4,8,24,168

3.33E+03
3.44E+03
5.43E+03
3.52E+03
2.21E+03
4.73E+03

8.01E-02
7.92E-02
1.26E-01
8.02E-02
5.03E-02
1.09E-01

2.00E-04
2.57E-04
3.01E-04
6.18E-04
4.97E-04
2.97E-04

5.67E-03
1.12E-02
1.32E-02
2.18E-02
4.97E-03
3.55E-03

6.3.7 Bias and MSE in Estimating Time of Peak Effect
In addition to examining the Bias and MSE associated with the
parameter estimates it is especially useful for the purposes of
benchmark dose estimation to investigate efficient designs for
estimating the TOPE. Since the TOPE is critical to benchmark dose
estimation, Bias and MSE of the TOPE estimator are useful criteria for
comparing designs. The 5 time point designs with 20 and 30 subjects
per dose group were assessed with respect to identifying the design
that recorded the smallest Bias and MSE for each dose group specific
TOPE. For the both the 20 and 30 subject designs, the Bias was within
one half hour of the true TOPE for each of the dose groups. The MSE
appeared relatively invariant to design for all dose groups except for
the lowest dose group (0.85mg/kg) which had the highest magnitude
in MSE overall (Figures 13 and 14) and seemed to benefit most from
designs where the testing times were closest to the true TOPE. This
lowest dose group is especially important to consider because of its
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relevance in establishing a Reference Dose used to define safe
exposure limits.
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Figure 13. Bias (Top) and Mean Square Error (Bottom) of the TOPE
estimator under the 5-time point 20 subject designs.
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Figure 14. Bias (Top) and Mean Square Error (Bottom) of the TOPE
estimator under the 5-time point 30 subject designs.
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Confidence intervals around the TOPE estimates were generated for
each of the 5 time point, 20 and 30 subject replicate design trials to
compare the ability of each design to recover the true TOPE (Table
15). As shown by the bias and MSE figures the variability in TOPE
estimation was largest for the lowest dose group. As dose levels
increased, the confidence intervals were within +/- one hour of the
true TOPE (Table 15). The results of the TOPE analysis indicate that
the biphasic model predicts the TOPE with validity (small bias) and
that the reliability of the TOPE estimate (MSE) seems to be dependent
on the number of subjects as well as the location of testing times,
especially for the lowest dose group). Testing times located in
proximity to the true TOPE for each dose group appeared to increase
the reliability of the estimate for that dose group.
Table 15. Confidence intervals for dose group specific TOPE for each of
the 5 time point, 20 subject designs. Confidence intervals were
generated by calculating the 2.5% and 97.5% of the distribution of
1000 TOPE estimates for each design.
Dose Group
20 Subject
Designs
0,2,4,24,168
0,2,8,24,168
0,2,12,24,168
0,2,16,24,168
0,2,20,24,168
0,4,8,24,168
0,4,12,24,168
0,8,12,24,168

0.85
12 (9-15)
12 (9-14)
12 (9-14)
12 (9-14)
12 (9-15)
12 (10-14)
12 (9-14)
12 (9-14)

1.69
9
9
9
9
9
9
9
9

(8-11)
(8-10)
(8-10)
(8-10)
(8-11)
(8-10)
(8-10)
(8-10)
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3.38
7
7
7
7
7
7
7
7

(7-8)
(7-8)
(7-8)
(7-8)
(7-8)
(6-8)
(6-8)
(6-8)

6.75
7
7
7
7
7
7
7
7

(5-8)
(5-8)
(5-8)
(5-8)
(5-8)
(5-8)
(5-8)
(6-8)

Table 16. Confidence intervals for dose group specific TOPE for each of
the 5 time point, 30 subject designs. Confidence intervals were
generated by calculating the 2.5% and 97.5% of the distribution of
1000 TOPE estimates for each design.
Dose Group
30 Subject
Designs
0,2,4,24,168
0,2,8,24,168
0,2,12,24,168
0,2,16,24,168
0,2,20,24,168
0,4,8,24,168
0,4,12,24,168
0,8,12,24,168

0.85
12 (10-15)
12 (10-14)
12 (9-14)
12 (9-14)
12 (9-14)
12 (9-14)
12 (10-14)
12 (10-14)

1.69
9
9
9
9
9
9
9
9

(8-11)
(8-10)
(8-10)
(8-10)
(8-10)
(8-10)
(8-10)
(8-10)
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3.38
7
7
7
7
7
7
7
7

(7-8)
(7-8)
(7-8)
(7-8)
(7-8)
(7-8)
(7-8)
(6-8)

6.75
7
7
7
7
7
7
7
7

(5-8)
(6-8)
(6-8)
(6-8)
(6-8)
(6-8)
(6-8)
(6-8)

Chapter 7
Conclusions
In this thesis we have developed a biphasic toxico-diffusion
model to describe dose-dependent time of peak effect (TOPE) in
neurobehavioral toxicity screening studies. The model has been
applied to a dataset from the IPCS collaborative study testing the
neurotoxic potential of the chemical parathion using motor activity
counts. The biphasic model predicted a decrease in motor activity
counts as dose increased with a dose-accelerated TOPE: 11.5 hrs in
the lowest dose group to 7.1 hrs in the highest dose group. The
biphasic model was a significant improvement relative to the fit of the
toxico-diffusion model according to the LRT as well as AIC and BIC.
Due to the limited amount of data, however, estimates for parameters
B and C were not statistically significant. Estimates of TOPE varied
greatly between the two models with the toxico-diffusion model
predicting a TOPE irrespective of dose at 26 hours while the biphasic
model predicted a TOPE between 7-12 hours, decreasing with higher
dose levels. Further, the magnitude of peak response (activity count at
the TOPE) was dramatically different between the two models. Under
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the toxico-diffusion model the minimum activity count was predicted to
be 100 at the highest dose level, whereas under the biphasic model
the peak response was predicted to be an activity count of 3 (the
observed response in the data). This difference in magnitude could
have dramatic impacts on benchmark dose estimation.
The simulation experiments identified the limitations of the
existing FOB design protocol for eliciting physiologically relevant doseresponse information and explored possible design improvements in
order to generate adequate data for dose-response modeling. A
specific focus of the simulation was to investigate the sensitivity of the
experiments with respect to dose-dependent TOPE. Our results
suggest that under the present experimental protocol of the FOB
study, there is a substantial lack of statistical power when fitting a
model such as the biphasic model. Only when the time spacing is
adequate will information about the true shape in time be available to
predict the dose-response relationship with validity. Does-dependent
TOPE’s cannot be verified if there are only limited time points in the
experiment. In this regard, the existing protocol of FOB is unlikely to
generate data that support dose-dependent TOPE. The simulation
results further demonstrated that the design protocol can be altered to
gain sensitivity and statistical power by adding additional time points
and/or additional subjects to each dose group in the experimental
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design. By adding a fifth experimental testing time point between hour
2 and 24, the sensitivity of the biphasic model improved with regard to
estimating the dose-dependent time trajectory (e.g. TOPE) as
witnessed by the increased model fitting convergence rate. By adding
an additional time point, there are also more data points leading to an
increase in statistical power for detecting the kinetic parameter Keo,
which determines the dose-dependent TOPE. Further increases in
power can be achieved by adding additional subjects. It is debatable,
however, whether it is practical to have at least 30 subjects per dose
group in these screening tests. In suggesting design protocol
improvements, consideration must be given to the practicality of any
suggested design for implementation within the framework of the EPA
testing guidelines for acute neurotoxicity.
An objective of the IPSC studies was to validate the study
protocol across participating laboratories. As a result, several
laboratories conducted experiments on the same chemical using
identical methodologies. However, each individual laboratory identified
the TOPE of the chemical through a pilot study and used that TOPE
estimate as the second testing time for the FOB experiments. Since
the definition of motor activity counts and the placement of the 2nd
testing time were left to the discretion of the individual laboratories,
there are concerns about pooling data across laboratories for statistical
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inference. Studies such as the IPCS would benefit from an
experimental design which standardized the approach to TOPE
estimation and motor activity counts in such a way that these data
could be pooled across laboratories. The example below considers
possible alternatives to the IPCS design that may effectively allow for
more physiologically relevant information to be obtained without
substantial investment of additional resources.
The IPCS collaborative studies rely on TOPE estimates from
range finding studies using gate and arousal scores; however, there is
evidence that different functional domains may exhibit different time
courses following acute chemical exposure (Lammers and Kulig, 1997.
Presuming that the TOPE for a given endpoint is measured without
error, testing endpoints in more functional domains would yield a
range of possible TOPE’s for chemical exposure. This range of TOPE’s
for the given chemical could be used to guide time point selection.
For example, even using only gait and arousal scores it is quite
possible that the TOPE was different for these scores yet only one time
point was chosen to represent the TOPE for the IPCS studies. As an
alternative to the design above, a testing time associated with each
TOPE (in this case 2) could be randomly assigned to participating
laboratories. The data across laboratories could then be pooled
resulting in a dataset where testing times for each TOPE estimate were
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captured while each participating laboratory would only perform the
experiments using 4 testing times. Mixed models such as those
developed in this thesis allow for missing information from the
individual time trajectories that would result from pooling these data.
This flexibility a critical advantage of using mixed effects models for
dose-response assessment compared to traditional methods such as
analysis of variance. A scenario such as the example above could be
expanded by considering a situation in which 5 metrics were used in
the pilot studies to represent a neurobehavioral endpoint from each of
5 functional domains. A range of potential TOPE’s could be established
from these experiments. Each laboratory could be randomly assigned a
testing time within the established range of TOPE’s. Once the data
were pooled, the resulting dataset would have numerous time points
for analysis; a scenario more consistent with kinetic studies used to
estimate physiological properties of the time course of a chemical in an
organism after exposure. Toyinbo (2004) has shown that for
functional domain composite scores, the precision of the TOPE
estimate is somewhat insensitive to the actual time of TOPE but that
the MSE appeared to be minimized when the time points were chosen
prior to the actual time of peak effect. Our findings suggest that
testing times bracketing the dose-dependent TOPE’s minimized the
imprecision of the TOPE estimator and increased the power of the
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model. By adding even two time points bracketing the range of TOPE’s
from range finding studies, the experimental design would be capable
of capturing more information for more neurobehavioral endpoints.
Another possible design protocol would be to choose distinct
time points for different dose group in anticipation that the TOPE may
dose-dependent. Since the range finding studies used a single dose for
the TOPE estimate, if the chemical possesses dose-dependent TOPE,
obviously a single testing time would capture the TOPE only for that
dose. If information were available on potential dose-dependent TOPE
for a given chemical under study, defining dose specific time points for
the experiment would yield relevant dose-dependent information
related to TOPE while maintaining the current sampling effort.
Adding additional subjects in each dose group would also
improve estimates of the dose group specific average response which
should increase the statistic power to detect significant response to
chemical exposure, but only if the testing times are chosen
appropriately would the benchmark dose estimation procedures be
improved.
This thesis makes several simplifying assumptions in attempting
to link mathematical models to pharmacologically relevant parameter
estimates. Bioavailability of oral induced exposure to parathion is
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assumed to be 100%. Further, absorption from the gastrointestinal
tract is assumed to be in rapid equilibrium with concentration in the
plasma compartment. From there it is the distributional delay
associated with the hypothesized effects compartment that governs
the dose-dependent TOPE observed in the data. There is some
evidence that parathion and its toxic metabolite paraoxon is a
chemical that induces non additive biochemical reactions in
experimental subjects (INCHEM 2004). The biphasic toxico-diffusion
imposed this dose-dependent TOPE but further study is necessary to
validate this as a mechanistic product of parathion exposure.
The case of delayed TOPE was not illustrated in this thesis but a
model was presented which may be useful in assessing dosedependent TOPE arising from capacity limited kinetics. These
situations have been observed in the literature (Dayneka et al. 1993,
Jusko et al.,1995; Krzyzanski and Jusko 1997) though no examples of
delayed effects with increasing dose were observed in the IPCS data.
The Nonlinear mixed effects models described in this thesis do
not stand in isolation for assessment the neurotoxic potential
associated with chemical exposure. Rather, the models serve to
support a framework of different tools including hazard
characterization, exposure assessment, risk characterization as well as
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dose-response assessment utilized to build consensus on the potential
risks associated with toxicity of the tested chemical. These tools are
intended to support and not to replace the expert judgments of
toxicologists who remain the key to understanding the implications of
any inference of chemical exposure. This thesis has provided an
additional tool that can be used in this regard and has illustrated its
potential benefits when assessing neurotoxic potential of chemical
exposure. It has further expanded the capability of risk assessment
researchers to capture the diverse and sometimes complex aspects of
dose-response relationships and contributed to the EPA’s aims to use
more physiologically relevant models to predict dose-response
relationships over the time course of experimental studies.
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